» Articles » PMID: 32472454

Challenges in Early Phase Clinical Trials for Childhood Cancer During the COVID-19 Pandemic: a Report from the New Agents Group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

Overview
Specialty Oncology
Date 2020 May 31
PMID 32472454
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The COVID-19 pandemic has forced healthcare stakeholders towards challenging decisions. We analyse the impact of the pandemic on the conduct of phase I-II trials for paediatric cancer during the first month of state of alarm in Spain.

Methods: A questionnaire was sent to all five ITCC-accredited Spanish Paediatric Oncology Early Phase Clinical Trial Units, including questions about impact on staff activities, recruitment, patient care, supply of investigational products, and legal aspects.

Results: All units suffered personnel shortages and difficulties in enrolling patients, treatment continuity, or performing trial assessments. Monitoring activity was frequently postponed (73%), and 49% of on-going trials interrupted recruitment. Only two patients could be recruited during this period (75% reduction in the expected rate).

Conclusions: The COVID-19 crisis has significantly impacted clinical research practice and access to innovation for children with cancer. Structural and functional changes are under way to better cope with the expected future restrictions.

Citing Articles

Research staff's experiences of how the COVID-19 pandemic impacted recruitment for a paediatric network study.

Fishman I, Henderson S, Vadeboncoeur C Int J Qual Stud Health Well-being. 2024; 19(1):2419158.

PMID: 39437222 PMC: 11497574. DOI: 10.1080/17482631.2024.2419158.


Neurofibromatosis: New Clinical Challenges in the Era of COVID-19.

Ardizzone A, Capra A, Campolo M, Filippone A, Esposito E, Briuglia S Biomedicines. 2022; 10(5).

PMID: 35625677 PMC: 9138859. DOI: 10.3390/biomedicines10050940.


The Global Impact of COVID-19 on Childhood Cancer Outcomes and Care Delivery - A Systematic Review.

Majeed A, Wright T, Guo B, Arora R, Lam C, Martiniuk A Front Oncol. 2022; 12:869752.

PMID: 35463381 PMC: 9023072. DOI: 10.3389/fonc.2022.869752.


Impact of COVID-19 measures on a paediatric oncology outreach-program.

El Salih I, Widjajanto P, Njuguna F, Kaspers G, Mostert S Psychooncology. 2022; 31(5):860-864.

PMID: 35403292 PMC: 9088594. DOI: 10.1002/pon.5934.


Incidence of childhood cancer in Canada during the COVID-19 pandemic.

Pelland-Marcotte M, Xie L, Barber R, Elkhalifa S, Frechette M, Kaur J CMAJ. 2021; 193(47):E1798-E1806.

PMID: 34844937 PMC: 8654886. DOI: 10.1503/cmaj.210659.


References
1.
Laetsch T, Dubois S, Mascarenhas L, Turpin B, Federman N, Albert C . Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018; 19(5):705-714. PMC: 5949072. DOI: 10.1016/S1470-2045(18)30119-0. View

2.
Bouffet E, Challinor J, Sullivan M, Biondi A, Rodriguez-Galindo C, Pritchard-Jones K . Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. Pediatr Blood Cancer. 2020; 67(7):e28327. DOI: 10.1002/pbc.28327. View

3.
Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T . Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Ann Oncol. 2020; 31(5):553-555. PMC: 7174827. DOI: 10.1016/j.annonc.2020.03.286. View

4.
Paul S, Mytelka D, Dunwiddie C, Persinger C, Munos B, Lindborg S . How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010; 9(3):203-14. DOI: 10.1038/nrd3078. View

5.
Chen Z, Xiong H, Li J, Li H, Tao F, Yang Y . [COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report]. Zhonghua Xue Ye Xue Za Zhi. 2020; 41(4):341-343. PMC: 7364917. DOI: 10.3760/cma.j.issn.0253-2727.2020.0004. View